scholarly journals Cell division cycle 20 overexpression predicts poor prognosis for patients with lung adenocarcinoma

Tumor Biology ◽  
2017 ◽  
Vol 39 (3) ◽  
pp. 101042831769223 ◽  
Author(s):  
Run Shi ◽  
Qi Sun ◽  
Jing Sun ◽  
Xin Wang ◽  
Wenjie Xia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Division ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Poor Prognosis ◽  
Small Cell ◽  
Cell Division Cycle ◽  
Small Cell Lung

The cell division cycle 20, a key component of spindle assembly checkpoint, is an essential activator of the anaphase-promoting complex. Aberrant expression of cell division cycle 20 has been detected in various human cancers. However, its clinical significance has never been deeply investigated in non-small-cell lung cancer. By analyzing The Cancer Genome Atlas database and using some certain online databases, we validated overexpression of cell division cycle 20 in both messenger RNA and protein levels, explored its clinical significance, and evaluated the prognostic role of cell division cycle 20 in non-small-cell lung cancer. Cell division cycle 20 expression was significantly correlated with sex (p = 0.003), histological classification (p < 0.0001), and tumor size (p = 0.0116) in non-small-cell lung cancer patients. In lung adenocarcinoma patients, overexpression of cell division cycle 20 was significantly associated with bigger primary tumor size (p = 0.0023), higher MKI67 level (r = 0.7618, p < 0.0001), higher DNA ploidy level (p < 0.0001), and poor prognosis (hazard ratio = 2.39, confidence interval: 1.87–3.05, p < 0.0001). However, in lung squamous cell carcinoma patients, no significant association of cell division cycle 20 expression was observed with any clinical parameter or prognosis. Overexpression of cell division cycle 20 is associated with poor prognosis in lung adenocarcinoma patients, and its overexpression can also be used to identify high-risk groups. In conclusion, cell division cycle 20 might serve as a potential biomarker for lung adenocarcinoma patients.

scholarly journals Screening prognostic markers for non-small cell lung cancer based on data mining and bioinformatics analysis

2020 ◽  
Author(s):  
Bin Han ◽  
Kaushik Chandra Aman ◽  
Dongqing Wei ◽  
Shulin Zhang ◽  
Minjie Meng
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Differentially Expressed Genes ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Prognostic Markers ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung

Abstract Background At present, non-small cell lung cancer has a high morbidity and mortality, and the recurrence and metastasis situation is serious. It is impossible to accurately predict the prognosis of cancer patients clinically. Biomarker is a kind of biomolecule with wide application prospects, and its potential in cancer prognosis is gradually revealed, and it is expected to be applied clinically. Results We integrated four gene expression profiles (GSE19188, GSE19804, GSE101929 and GSE18842) from the GEO database and screened the commonly differentially expressed genes using the GEO2R online tool. We screened 952 commonly differentially expressed genes. Gene ontology analysis showed that CDEGs were mainly enriched in biological processes such as cell adherin, angiogenesis and positive regulation of angiogenesis, and KEGG pathways such as ECM-receptor interaction and cell adherin molecules (CAMs). Up-regulation of G2 and S phase-expressed protein 1(GTSE1) expression is associated with poor prognosis of lung adenocarcinoma(LADE) and lung squamous cell carcinoma(LUSC). Up-regulation of Neuromedin-U(NMU) expression, down-regulation of Proto-oncogene c-Fos(FOS) and Cyclin-dependent kinase inhibitor 1C(CDKN1C) is only associated with poor prognosis of LADE. Conclusions We believe that GTSE1, NMU, FOS, and CDKN1C have potential application value as prognostic markers for lung adenocarcinoma, and are of great significance for lung adeno carcinoma efficacy evaluation and relapse monitoring. At the same time, GTSE1 may also be used as a new target for cancer treatment New ways.

scholarly journals CDC25AQ110del: A Novel Cell Division Cycle 25A Isoform Aberrantly Expressed in Non-Small Cell Lung Cancer

PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e46464 ◽  
Author(s):  
Rania H. Younis ◽  
Wei Cao ◽  
Ruxian Lin ◽  
Ronghui Xia ◽  
Zhenqiu Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Division ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cell Division Cycle ◽  
Small Cell Lung

LIFE SPAN PREDICTION AT METASTATIC NON-SMALL CELL LUNG CANCER

2018 ◽  
Vol 64 (4) ◽  
pp. 522-527
Author(s):  
Aleksey Shutko ◽  
Viktor Mus
Keyword(s):  
Lung Cancer ◽  
Stem Cells ◽  
Small Cell Lung Cancer ◽  
Life Span ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
Hemopoietic Stem Cells ◽  
Small Cell Lung ◽  
Individual Life

Individual parameters of circulating hemopoietic stem cells (HSC) lymphoid origin were measured by cytofluorometry before treatment of patients with metastatic non-small cell lung cancer and were retrospectively compared with individual life span's (LS). The possibility of poor prognosis of treatment's results (LS

scholarly journals High expression of Stabilin-2 predicts poor prognosis in non-small-cell lung cancer

Bioengineered ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 3426-3433
Author(s):  
Juanjuan Yong ◽  
Liyun Huang ◽  
Gengbiao Chen ◽  
Xiaoya Luo ◽  
Hui Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
High Expression ◽  
Small Cell Lung

scholarly journals Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer

2017 ◽  
Vol 14 (4) ◽  
pp. 3959-3966 ◽  
Author(s):  
Dan Liu ◽  
Yi Huang ◽  
Li Zhang ◽  
Dong-Ni Liang ◽  
Li Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
Janus Kinase ◽  
Small Cell Lung ◽  
Janus Kinase 1

scholarly journals Upregulation of IL-11, an IL-6 Family Cytokine, Promotes Tumor Progression and Correlates with Poor Prognosis in Non-Small Cell Lung Cancer

2018 ◽  
Vol 45 (6) ◽  
pp. 2213-2224 ◽  
Author(s):  
Meng Zhao ◽  
Yahui Liu ◽  
Ran Liu ◽  
Jin Qi ◽  
Yongwang Hou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Epithelial Mesenchymal Transition ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mesenchymal Transition

Background/Aims: Cytokines are key players in tumorigenesis and are potential targets in cancer treatment. Although IL-6 has attracted considerable attention, interleukin 11 (IL-11), another member of the IL-6 family, has long been overlooked, and little is known regarding its specific function in non-small cell lung cancer (NSCLC). In this study, we explored IL-11’s role in NSCLC and the detailed mechanism behind it. Methods: Cell proliferation in response to IL-11 was determined by colony formation, BrdU incorporation and MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. Cell motility was measured by Transwell and wound healing assays. NSCLC xenograft models were used to confirm oncogenic function of IL-11 in vivo. Immunohistochemical staining and western blot assay were performed to detect epithelial–mesenchymal transition (EMT) markers and cell signaling pathway alterations. Eighteen NSCLC patients and 5 normal lung samples were collected together with data from an online database to determine the link between IL-11 expression and malignant progression. Results: We observed that IL-11 was upregulated in NSCLC samples compared with normal tissue samples and correlated with poor prognosis. Data from in vitro and in vivo models indicated that IL-11 promotes cell proliferation and tumorigenesis. Cell migration and invasion were also enhanced by IL-11. Epithelial–mesenchymal transition (EMT) was also observed after IL-11 incubation. Furthermore, IL-11 activated AKT and STAT3 in our experimental models. In addition, we observed that hypoxia induced IL-11 expression in NSCLC cells. Deferoxamine (DFX) or dimethyloxalylglycine (DMOG) induced hypoxia-inducible factor 1-alpha (HIF1α) upregulation, which enhanced IL-11 expression in NSCLC cells. Conclusions: Taken together, our results indicate that IL-11 is an oncogene in NSCLC, and elucidating the mechanism behind it may provide insights for NSCLC treatment.

Overexpression of HP1γ is associated with poor prognosis in non-small cell lung cancer cell through promoting cell survival

Tumor Biology ◽  
2014 ◽  
Vol 35 (10) ◽  
pp. 9777-9785 ◽  
Author(s):  
Ji Zhou ◽  
Hui Bi ◽  
Ping Zhan ◽  
Cunjie Chang ◽  
Chunhua Xu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Survival ◽  
Cancer Cell ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Small Cell ◽  
Lung Cancer Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document